HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALEBUND-B

24.020

-0.980-3.92%

Volume:563.40K

Turnover:13.65M

Market Cap:8.36B

PE:-7.82

High:25.300

Open:25.000

Low:23.820

Close:25.000

52wk High:46.820

52wk Low:22.720

Shares:348.00M

HK Float Shares:236.00M

Volume Ratio:0.41

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-3.071

ROE:--

ROA:-33.01%

PB:5.08

PE(LYR):-7.82

PS:58.32

Loading ...

Overview Company News Filings

Alebund Pharmaceuticals (Jiangsu) Says IND Application for AP308 Cleared by U.S. FDA

ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308

Alebund Pharmaceuticals (Jiangsu) - AP308 Clinical Trial Planned Soon Following FDA Ind Clearance

THOMSON REUTERS

Alebund Pharma Wins US FDA Clearance to Start AP308 IgA Nephropathy Trial

Alebund Pharmaceuticals (Jiangsu) - Investigational New Drug Application for AP308 for Treatment of Iga Nephropathy Cleared by U.S. FDA

THOMSON REUTERS

HK Grey Market | EXCELLAND ROBOT Surges Over 93%, Generating Over HK$2,700 in Paper Gains Per Lot

Tiger Newspress

Hong Kong Stock Market Alert | ALEBUND-B (09637) Surges Over 6% on Stock Connect Inclusion and Index Membership, Mircera Sales Jump Approximately 105% Boosting Commercial Momentum

Alebund Pharma Added to Two Chinese Stock Connect Programs

MT Newswires Live

ALEBUND-B Announced H Shares Inclusion in Stock Connect and Hang Seng Composite Index

ALEBUND-B (09637) H Shares Set to Join Stock Connect and Hang Seng Composite Index

Unpacking ALEBUND-B's First Half Results: The Compounding Growth Logic of a Kidney Disease-Focused Biopharma

Alebund Pharmaceuticals HY26 Net Loss Narrows 22.5% to RMB 162.55 Million; Revenue Rises to RMB 104.16 Million

Alebund Pharmaceuticals (Jiangsu) Ltd - Board Did not Recommend Distribution of an Interim Dividend

THOMSON REUTERS

Alebund Pharmaceuticals (Jiangsu) Ltd - Hy Loss Attributable Rmb162.6 Mln

THOMSON REUTERS

Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth

Earning Preview: ALEBUND-B Q2 revenue expected to increase, institutions cautious on margin recovery

Alebund Pharmaceuticals Held Extraordinary General Meeting; Auditor Appointment Approved

Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results

Bulletin Express

Alebund Pharmaceuticals Schedules Board Meeting to Review Interim Results

Alebund Pharma's Application for Hyperphosphatemia Drug Accepted in China

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/09637/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"09637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"ALEBUND-B","latestPrice":24.02,"timestamp":1789114134177,"preClose":25,"halted":0,"volume":563400,"delay":0,"changeRate":-0.03920000000000002,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"Not Yet Opened","change":-0.98,"latestTime":"09-11 16:08:54","open":25,"high":25.3,"low":23.82,"amount":13646814,"amplitude":0.0592,"askPrice":24.12,"askSize":100,"bidPrice":24.02,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-2.326,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":25,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.4095539321862368,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","floatShares":236000000,"roa":"-33.01%","roe":"--","lyrEps":-3.071284,"volumeRatio":0.4095539321862368,"shares":348000000,"dividePrice":0,"high":25.3,"amplitude":0.0592,"preClose":25,"low":23.82,"week52Low":22.72,"pbRate":"5.08","psRate":"58.32","week52High":46.82,"institutionHeld":0,"latestPrice":24.02,"committee":0.5,"eps":-3.071284,"divideRate":0,"volume":563400,"delay":0,"ttmEps":-2.326,"open":25,"prevYearClose":22.6,"prevWeekClose":24.02,"prevMonthClose":31.48,"prevQuarterClose":45.92,"fiveDayClose":28.8,"twentyDayClose":33.48,"sixtyDayClose":22.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09637\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"09637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":3,"updateTime":1787846400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09637","date":"2026-09-11","current":-10.326741,"percent":0.943396,"low":-18.066068,"twenty":-12.953815,"median":-11.760082,"eighty":-10.889159,"high":-8.42626,"avg":-11.942413,"sd":1.739789,"marketCap":8163250588},"quantilePoints":[{"date":"2026-06-26","current":-8.87585,"twenty":-8.87585,"median":-8.87585,"eighty":-8.87585,"marketCap":7680660420},{"date":"2026-07-03","current":-11.883178,"twenty":-18.03155,"median":-11.883178,"eighty":-9.78101,"marketCap":10290725554},{"date":"2026-07-10","current":-12.164969,"twenty":-13.966639,"median":-11.847257,"eighty":-11.12129,"marketCap":10521825071},{"date":"2026-07-17","current":-10.947234,"twenty":-12.322489,"median":-11.455859,"eighty":-10.783874,"marketCap":9502268378},{"date":"2026-07-24","current":-11.320561,"twenty":-11.939536,"median":-11.377389,"eighty":-10.939493,"marketCap":9828526520},{"date":"2026-07-31","current":-10.642718,"twenty":-11.840073,"median":-11.194259,"eighty":-10.78337,"marketCap":9257574772},{"date":"2026-08-07","current":-12.743391,"twenty":-12.396338,"median":-11.399787,"eighty":-10.889159,"marketCap":11106370909},{"date":"2026-08-14","current":-13.03884,"twenty":-12.987078,"median":-11.462395,"eighty":-10.903987,"marketCap":11378252693},{"date":"2026-08-21","current":-12.870195,"twenty":-13.077865,"median":-11.725167,"eighty":-10.931752,"marketCap":11255905890},{"date":"2026-08-28","current":-12.144658,"twenty":-13.077865,"median":-11.990608,"eighty":-10.959851,"marketCap":10623780741},{"date":"2026-09-04","current":-11.919154,"twenty":-12.988947,"median":-11.883178,"eighty":-10.931752,"marketCap":9787744252},{"date":"2026-09-11","current":-9.927508,"twenty":-12.953815,"median":-11.760082,"eighty":-10.889159,"marketCap":8163250588}],"updateTime":1789333276847},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09637\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665431379","title":"Alebund Pharmaceuticals (Jiangsu) Says IND Application for AP308 Cleared by U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665431379","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665431379?lang=en_us&edition=fundamental","pubTime":"2026-09-08 23:31","pubTimestamp":1788881494,"startTime":"0","endTime":"0","summary":"Sept 8 (Reuters) - Alebund Pharmaceuticals (Jiangsu) Ltd <9637.HK>::*INVESTIGATIONAL NEW DRUG APPLICATION FOR AP308 FOR TREATMENT OF IGA NEPHROPATHY CLEARED BY U.S. FDA*Further company coverage: 9637.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nRSDYgyKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141807270","title":"ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308","url":"https://stock-news.laohu8.com/highlight/detail?id=1141807270","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141807270?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:06","pubTimestamp":1788869176,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BMED","BK1191","BK1515","PSYK","BK1161","MDTX","IBBJ","IBBQ","BK1574","159151","09637","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665416320","title":"Alebund Pharmaceuticals (Jiangsu) - AP308 Clinical Trial Planned Soon Following FDA Ind Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2665416320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665416320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:05","pubTimestamp":1788869101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA2NDWZM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132055","title":"Alebund Pharma Wins US FDA Clearance to Start AP308 IgA Nephropathy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665132055?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868895,"startTime":"0","endTime":"0","summary":"Alebund Pharma wins US FDA clearance to start AP308 IgA nephropathy trialAlebund Pharmaceuticals (Jiangsu) secured FDA clearance for an IND for AP308 in IgA nephropathy.Approval enables the start of a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL3brvHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320340","title":"Alebund Pharmaceuticals (Jiangsu) - Investigational New Drug Application for AP308 for Treatment of Iga Nephropathy Cleared by U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320340?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868836,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN4500RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109204741","title":"HK Grey Market | EXCELLAND ROBOT Surges Over 93%, Generating Over HK$2,700 in Paper Gains Per Lot","url":"https://stock-news.laohu8.com/highlight/detail?id=1109204741","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109204741?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:28","pubTimestamp":1788856095,"startTime":"0","endTime":"0","summary":"On Tuesday,  $EXCELLAND ROBOT(03231)$ surged over 93% in Hong Kong grey market trading. According to the prospectus, the company's revenue comes from sales of robot products and modules, AI vision...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03231","09637","01191","02672"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1183000307","title":"Hong Kong Stock Market Alert | ALEBUND-B (09637) Surges Over 6% on Stock Connect Inclusion and Index Membership, Mircera Sales Jump Approximately 105% Boosting Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1183000307","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183000307?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:22","pubTimestamp":1788834140,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) shares climbed more than 6% in Monday's session, trading up 6.02% at HK$28.52 as of the time of writing. The stock recorded a turnover of HK$6.452 million with a volume ratio of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK1161","BK4585","09637","09939","HSCI","BK1574","KCAI","BK1515","BK1191","FLHK","159938","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392411","title":"Alebund Pharma Added to Two Chinese Stock Connect Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392411","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665392411?lang=en_us&edition=fundamental","pubTime":"2026-09-07 15:15","pubTimestamp":1788765338,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals'  Hong Kong-listed shares have been included in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs effective Monday.The company believes its inclusion in the cross-border trading links will help broaden its investor base and boost the trading liquidity of its shares, according to a Monday bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["YANG","YINN","XPP","02822","82843","82822","09637","ASHR","BK1191","FLCH","02823","KCAI","KBA","CWEB","YXI","ASHS","FXP","CHAU","02843","KWEB","82823"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187807186","title":"ALEBUND-B Announced H Shares Inclusion in Stock Connect and Hang Seng Composite Index","url":"https://stock-news.laohu8.com/highlight/detail?id=1187807186","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187807186?lang=en_us&edition=fundamental","pubTime":"2026-09-07 09:00","pubTimestamp":1788742832,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) has announced that, in accordance with the relevant arrangements and adjustments for Stock Connect, its H shares have been included in the list of eligible securities for Stock...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","HSCI","FLHK","09939","159938","BK1515","BK1161","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144923293","title":"ALEBUND-B (09637) H Shares Set to Join Stock Connect and Hang Seng Composite Index","url":"https://stock-news.laohu8.com/highlight/detail?id=1144923293","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144923293?lang=en_us&edition=fundamental","pubTime":"2026-09-04 21:36","pubTimestamp":1788528973,"startTime":"0","endTime":"0","summary":"The Board of ALEBUND-B (09637) has announced that its H shares have been included in the list of eligible securities under the Stock Connect programme. This inclusion will take effect from Monday,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","159938","BK1161","BK1574","09637","BK1515","HSCI","FLHK","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135812657","title":"Unpacking ALEBUND-B's First Half Results: The Compounding Growth Logic of a Kidney Disease-Focused Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1135812657","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135812657?lang=en_us&edition=fundamental","pubTime":"2026-08-27 08:04","pubTimestamp":1787789077,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) delivered its inaugural interim results on August 26, marking a significant milestone since its listing, with revenue scaling to 8.6 times the figure reported in the same period...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09637","159938","BK1161","BK1515","09939","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797855","title":"Alebund Pharmaceuticals HY26 Net Loss Narrows 22.5% to RMB 162.55 Million; Revenue Rises to RMB 104.16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797855","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797855?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:04","pubTimestamp":1787738650,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals HY26 net loss narrows 22.5% to RMB 162.55 million; revenue rises to RMB 104.16 millionAlebund posted revenue of RMB 104.16 million, up 761.2%, driven by RMB 79.3 million AP306 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL7Q1XP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792769","title":"Alebund Pharmaceuticals (Jiangsu) Ltd - Board Did not Recommend Distribution of an Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662792769?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:01","pubTimestamp":1787738462,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792744","title":"Alebund Pharmaceuticals (Jiangsu) Ltd - Hy Loss Attributable Rmb162.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662792744?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:01","pubTimestamp":1787738462,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0HX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143863458","title":"Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1143863458","media":"Stock News","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143863458?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:00","pubTimestamp":1787641221,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) climbed more than 6% in early trading, last up 3.82% at HK$33.7, with turnover reaching HK$12.45 million.On the news front, Hang Seng Indexes Company recently announced the results...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK4588","BK4585","09939","BK1515","KCAI","BK1191","159938","BK1161","VXUS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170273351","title":"Earning Preview: ALEBUND-B Q2 revenue expected to increase, institutions cautious on margin recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=1170273351","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170273351?lang=en_us&edition=fundamental","pubTime":"2026-08-19 11:23","pubTimestamp":1787109824,"startTime":"0","endTime":"0","summary":"Abstract Alebund Pharmaceuticals-B will report its quarterly results on August 26, 2026 post-Market; this preview summarizes the latest quarter’s performance, current-quarter forecasts on revenue,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: ALEBUND-B Q2 revenue expected to increase, institutions cautious on margin recovery","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659148546","title":"Alebund Pharmaceuticals Held Extraordinary General Meeting; Auditor Appointment Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2659148546","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659148546?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:17","pubTimestamp":1786702628,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals held extraordinary general meeting; auditor appointment approvedAlebund Pharmaceuticals (Jiangsu) held an extraordinary general meeting on Aug. 14, 2026.Shareholders adopted a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3qLvt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162000898","title":"Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1162000898","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162000898?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:43","pubTimestamp":1786621402,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659712159","title":"Alebund Pharmaceuticals Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659712159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659712159?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:36","pubTimestamp":1786621010,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals schedules board meeting to review interim resultsAlebund Pharmaceuticals scheduled a board meeting for Aug. 26, 2026.Directors are set to review interim results for the six mon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL8dQ2dZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657564891","title":"Alebund Pharma's Application for Hyperphosphatemia Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2657564891","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657564891?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:33","pubTimestamp":1786102380,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals 's  new drug application for AP301 capsules was accepted for review by China's National Medical Products Administration.The drug has been developed for the treatment of hyperphosphatemia in patients with chronic kidney disease receiving maintenance dialysis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}]}}